This invention discloses a comprehensive nutraceutical designed to antagonize major mitigating factors specific to the degenerative process that occurs in Parkinson's disease (PD). The formulation is comprised of pyruvate, succinate and/or oxaloacetate further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The formula is based on means to attenuate the loss of ATP/toxicity by PD model toxins: 1-methyl-4-phenylpyridinium and rotenone, scavenge hydrogen peroxide/O.sub.2, augment antioxidant enzymes, prevent dopamine oxidation to DA-quinone via inhibition of COX, PLA.sub.2, LOX, xanthine oxidase, tyrosinase, prevent hyperhomocysteinemia, antagonize PARP-1 apoptosis, increase blood flow, glucose and oxygen delivery to the brain, potentiate mitochondrial function, antagonize glia iNOS and MAO or its products, chelate redox-active iron, inhibit hemeoxygenase-1, inhibit alpha-synuclein aggregation, augment ATP storage, mediate anti-inflammatory effects via inhibition. of PDE, MAPK p38/c-Jun NH2-terminal kinase/PGE2, antagonize excitotoxicity and downregulate N-methyltransferase, all of which contribute toward PD pathology.